Suppr超能文献

接受心脏-肝脏联合移植的Fontan术患者与非Fontan术患者的围手术期特征及结局:一项回顾性队列研究

Perioperative Characteristics and Outcomes of Fontan Versus Non-Fontan Patients Undergoing Combined Heart-Liver Transplantation: A Retrospective Cohort Study.

作者信息

Wu Wei Kelly, Siegrist Kara K, Ziogas Ioannis A, Mishra Kelly L, Matsuoka Lea K, Menachem Jonathan N, Izzy Manhal, Shingina Alexandra, Do Nhue L, Bacchetta Matthew, Shah Ashish S, Alexopoulos Sophoclis P

机构信息

Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN; Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN.

Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN.

出版信息

J Cardiothorac Vasc Anesth. 2024 Mar;38(3):745-754. doi: 10.1053/j.jvca.2023.11.043. Epub 2023 Dec 4.

Abstract

OBJECTIVES

Combined heart-liver transplantation (CHLT) is becoming increasingly frequent as a maturing population of patients with Fontan-palliated congenital heart disease develop advanced liver fibrosis or cirrhosis. The authors present their experience with CHLT for congenital and noncongenital indications, and identify characteristics associated with poor outcomes that may guide intervention in high-risk patients.

DESIGN

This was a single-center retrospective cohort study.

SETTING

This study was conducted at Vanderbilt University Medical Center in Nashville, Tennessee.

PARTICIPANTS

The study included 16 consecutive adult recipients of CHLT at the authors' institution between April 2017 and February 2022.

INTERVENTIONS

Eleven patients underwent transplantation for Fontan indications, and 5 were transplanted for non-Fontan indications.

MEASUREMENTS AND MAIN RESULTS

Compared with non-Fontan patients, Fontan recipients had longer cardiopulmonary bypass duration (199 v 119 minutes, p =m0.002), operative times (786 v 599 minutes, p = 0.01), and larger blood product transfusions (15.4 v 6.3 L, p = 0.18). Six of 16 patients required extracorporeal membrane oxygenation (ECMO), of whom 4 were Fontan patients who subsequently died. Patients who required ECMO had lower 5-hour lactate clearance (0.0 v 3.5 mmol/L, p = 0.001), higher number of vasoactive infusions, lower pulmonary artery pulsatility indices (0.58 v 1.77, p = 0.03), and higher peak inspiratory pressures (28.0 v 18.5 mmHg, p = 0.01) after liver reperfusion.

CONCLUSIONS

Combined heart-liver transplantation in patients with Fontan-associated end-organ disease is particularly challenging and associated with higher recipient morbidity compared with non-Fontan-related CHLT. Early hemodynamic intervention for signs of ventricular dysfunction may improve outcomes in this growing high-risk population.

摘要

目的

随着接受Fontan姑息治疗的先天性心脏病患者群体逐渐成熟,并发晚期肝纤维化或肝硬化,心脏-肝脏联合移植(CHLT)越来越常见。作者介绍了他们在先天性和非先天性适应证CHLT方面的经验,并确定与不良预后相关的特征,以指导对高危患者的干预。

设计

这是一项单中心回顾性队列研究。

背景

本研究在田纳西州纳什维尔的范德比尔特大学医学中心进行。

参与者

该研究纳入了2017年4月至2022年2月期间在作者所在机构连续接受CHLT的16名成年受者。

干预措施

11例患者因Fontan适应证接受移植,5例因非Fontan适应证接受移植。

测量指标和主要结果

与非Fontan患者相比,Fontan受者的体外循环时间更长(199对119分钟,p = 0.002)、手术时间更长(786对599分钟,p = 0.01)、输血量大(15.4对6.3升,p = 0.18)。16例患者中有6例需要体外膜肺氧合(ECMO),其中4例是Fontan患者,随后死亡。需要ECMO的患者肝再灌注后5小时乳酸清除率较低(0.0对3.5毫摩尔/升,p = 0.001)、血管活性药物输注次数较多、肺动脉搏动指数较低(0.58对1.77,p = 0.03)、吸气峰压较高(28.0对18.5毫米汞柱,p = 0.01)。

结论

与非Fontan相关的CHLT相比,Fontan相关终末器官疾病患者的心脏-肝脏联合移植特别具有挑战性,且受者发病率更高。针对心室功能障碍迹象的早期血流动力学干预可能会改善这一不断增长的高危人群的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验